

PRODUCT INFORMATION



Xenin-25 (acetate)

Item No. 45528

Formal Name: L-methionyl-L-leucyl-L-threonyl-L-lysyl-L-phenylalanyl-L- α -glutamyl-L-threonyl-L-lysyl-L-seryl-L-alanyl-L-arginyl-L-valyl-L-lysylglycyl-L-leucyl-L-seryl-L-phenylalanyl-L-histidyl-L-prolyl-L-lysyl-L-arginyl-L-prolyl-L-tryptophyl-L-isoleucyl-L-leucine, acetate

Synonym: Xenopsin-25

Peptide Sequence: H-MLTKFETLSARVKGLSFHPKRPWIL-OH

MF: C₁₃₉H₂₂₄N₃₈O₃₂S • XC₂H₄O₂


FW: 2,971.6

Purity: \geq 98%

Supplied as: A solid

Storage: -20°C

Stability: \geq 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Xenin-25 (acetate) is supplied as a solid. A stock solution may be made by dissolving the xenin-25 (acetate) in the solvent of choice, which should be purged with an inert gas. Xenin-25 (acetate) is sparingly soluble (1-10 mg/ml) in acetonitrile:water (1:1).

Description

Xenin-25 is an endogenous peptide and a neurotensin (NTS) receptor ligand.¹ It binds to NTS receptors in HEK293 cell membranes expressing the mouse receptor. It is expressed in K cells in the small intestine and co-secreted with glucose-dependent insulinotropic polypeptide (GIP).² Xenin-25 (1 μ M) stimulates the release of insulin in BRIN-BD11 rat pancreatic β -cells in the presence of glucose and increases the insulinotropic response of glucagon-like peptide 1 (GLP-1), GIP, and neurotensin in the same cells.² It prevents increases in plasma glucose levels in mice when administered 30 minutes before a subcutaneous injection of glucose. Xenin-25 inhibits gastric acid release stimulated by pentagastrin (Item No. 28546), increases pancreatic protein secretion, and stimulates contraction of the jejunum in anesthetized dogs.³

References

1. Botto, J.M., Chabry, J., Sarret, P., *et al.* Stable expression of the mouse levocabastine-sensitive neurotensin receptor in HEK 293 cell line: Binding properties, photoaffinity labeling, and internalization mechanism. *Biochem. Biophys. Res. Commun.* **243(2)**, 585-590 (1998).
2. Taylor, A.I., Irwin, N., McKillop, A.M., *et al.* Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety. *J. Endocrinol.* **207(1)**, 87-93 (2010).
3. Feurle, G.E., Heger, M., Niebergall-Roth, E., *et al.* Gastroenteropancreatic effects of xenin in the dog. *J. Pept. Res.* **49(4)**, 324-330 (1997).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/15/2026

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM